백신 전달 장치 시장 보고서 : 디바이스, 투여 경로, 최종사용자, 지역별(2025-2033년)

The global vaccine delivery devices market size reached USD 8.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.3 Billion by 2033, exhibiting a growth rate (CAGR) of 6.28% during 2025-2033. The market is experiencing steady growth driven by the growing awareness and demand for vaccination, coupled with innovations such as needle-free injectors and microneedles, the rising prevalence of infectious diseases, and ongoing strategic collaborations among key players.

A vaccine is a biological substance used to protect individuals from bacterial illnesses by stimulating the immune response of the body against the disease. It helps the immune system to produce antibodies against the invading antigens when given at specific intervals. It can be delivered in the body through liposomes, microspheres, nanoparticles, dendrimers, micellar systems, immune stimulating complexes (ISCOMs), and plant-derived viruses. At present, there is a rise in the utilization of vaccine delivery devices due to the growing prevalence of infectious diseases across the globe.

Vaccine Delivery Devices Market Trends:

Technological advancements in the systematic delivery of vaccines, such as micro-needles and electroporation, represent one of the key factors driving the market. Moreover, there is an increase in the utilization of needle-free delivery systems as they decrease needle stick injuries and the vaccine antigen dose and enhance the vaccine immunogenicity. This, along with the rising research in the field of vaccines and the development of new vaccine delivery devices around the world, is propelling the growth of the market. In addition, governments of several countries are promoting immunization programs to prevent disabilities and deaths from vaccine-preventable diseases. This, coupled with the growing investments by non-governmental organizations (NGOs) for various vaccination programs and campaigns globally, is positively influencing the market. Besides this, key market players are focusing on novel delivery technologies that increase the therapeutic value of vaccines by reducing toxicity. Additionally, the expanding healthcare sector due to the increasing geriatric population and easy access to medical products and services is bolstering the market growth. Furthermore, the outbreak of coronavirus disease (COVID-19) is augmenting the sales of vaccine delivery devices worldwide.

Key Market Segmentation:

Breakup by Device:

• Syringes
• Jet Injectors
• Others

Breakup by Route of Administration:

• Intramuscular Vaccination
• Intradermal Vaccination
• Subcutaneous Vaccination
• Others

Breakup by End User:

• Hospitals
• Clinics
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Becton Dickinson and Company, Enesi Pharma Limited, Gerresheimer AG, INOVIO Pharmaceuticals, NanoPass, Panacea Biotec Pharma Limited (Panacea Biotec), Pharmajet Inc., Schott AG (Carl-Zeiss-Stiftung), Terumo Corporation and Vaxxas.

Key Questions Answered in This Report

• 1.What was the size of the global vaccine delivery devices market in 2024?
• 2.What is the expected growth rate of the global vaccine delivery devices market during 2025-2033?
• 3.What are the key factors driving the global vaccine delivery devices market?
• 4.What has been the impact of COVID-19 on the global vaccine delivery devices market?
• 5.What is the breakup of the global vaccine delivery devices market based on the device?
• 6.What is the breakup of the global vaccine delivery devices market based on the route of administration?
• 7.What is the breakup of the global vaccine delivery devices market based on end user?
• 8.What are the key regions in the global vaccine delivery devices market?
• 9.Who are the key players/companies in the global vaccine delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Vaccine Delivery Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Device

• 6.1 Syringes
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Jet Injectors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Intramuscular Vaccination
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Intradermal Vaccination
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Subcutaneous Vaccination
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 3M Company
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Becton Dickinson and Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Enesi Pharma Limited
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Gerresheimer AG
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 INOVIO Pharmaceuticals
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 NanoPass
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Panacea Biotec Pharma Limited (Panacea Biotec)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Pharmajet Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Schott AG (Carl-Zeiss-Stiftung)
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 SWOT Analysis
  • 14.3.10 Terumo Corporation
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Vaxxas
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio